Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proctocolectomy, Restorative | 6 | 2022 | 87 | 2.090 |
Why?
|
| Colonic Pouches | 5 | 2022 | 67 | 1.790 |
Why?
|
| Colitis, Ulcerative | 6 | 2022 | 711 | 1.380 |
Why?
|
| Digestive System Surgical Procedures | 4 | 2021 | 120 | 1.250 |
Why?
|
| Rectal Neoplasms | 2 | 2021 | 116 | 1.090 |
Why?
|
| Hypoalbuminemia | 1 | 2022 | 9 | 0.900 |
Why?
|
| Malnutrition | 1 | 2022 | 34 | 0.860 |
Why?
|
| Pressure Ulcer | 1 | 2022 | 42 | 0.860 |
Why?
|
| Burnout, Professional | 1 | 2022 | 94 | 0.770 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 736 | 0.750 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 938 | 0.680 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 317 | 0.680 |
Why?
|
| Surgeons | 1 | 2022 | 238 | 0.640 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 94 | 0.590 |
Why?
|
| Postoperative Complications | 7 | 2023 | 2207 | 0.580 |
Why?
|
| Nanostructures | 1 | 2017 | 77 | 0.560 |
Why?
|
| Pouchitis | 2 | 2021 | 44 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 1197 | 0.510 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 2232 | 0.450 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2019 | 455 | 0.440 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 1056 | 0.430 |
Why?
|
| MicroRNAs | 1 | 2017 | 534 | 0.420 |
Why?
|
| Microbiota | 2 | 2018 | 381 | 0.410 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 458 | 0.390 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 23 | 0.390 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2021 | 549 | 0.370 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 68 | 0.370 |
Why?
|
| Retrospective Studies | 9 | 2023 | 8477 | 0.360 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 71 | 0.340 |
Why?
|
| Anastomosis, Surgical | 3 | 2023 | 267 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 339 | 0.290 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.290 |
Why?
|
| HCT116 Cells | 2 | 2017 | 151 | 0.290 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 96 | 0.290 |
Why?
|
| Humans | 20 | 2023 | 86617 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 683 | 0.280 |
Why?
|
| Robotic Surgical Procedures | 1 | 2021 | 267 | 0.270 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2358 | 0.270 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.260 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.250 |
Why?
|
| Vaccination | 1 | 2016 | 254 | 0.250 |
Why?
|
| Radiotherapy | 1 | 2016 | 328 | 0.240 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 191 | 0.240 |
Why?
|
| Health Status | 1 | 2016 | 360 | 0.240 |
Why?
|
| Clostridium Infections | 1 | 2016 | 125 | 0.240 |
Why?
|
| Laparoscopy | 1 | 2021 | 754 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 567 | 0.230 |
Why?
|
| Colostomy | 1 | 2022 | 13 | 0.230 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 383 | 0.220 |
Why?
|
| Sepsis | 1 | 2016 | 306 | 0.220 |
Why?
|
| Professional Misconduct | 1 | 2022 | 25 | 0.220 |
Why?
|
| Professionalism | 1 | 2022 | 24 | 0.210 |
Why?
|
| Albumins | 1 | 2022 | 133 | 0.210 |
Why?
|
| Anal Canal | 1 | 2022 | 89 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2016 | 629 | 0.190 |
Why?
|
| Quality of Life | 1 | 2019 | 1583 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 645 | 0.190 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 301 | 0.170 |
Why?
|
| Survival Analysis | 2 | 2017 | 1538 | 0.170 |
Why?
|
| Receptors, Drug | 1 | 2008 | 54 | 0.160 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1464 | 0.160 |
Why?
|
| Colitis | 1 | 2021 | 239 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 141 | 0.160 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2008 | 119 | 0.150 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2017 | 13 | 0.150 |
Why?
|
| Crohn Disease | 1 | 2023 | 730 | 0.150 |
Why?
|
| Risk Factors | 2 | 2022 | 5417 | 0.150 |
Why?
|
| Drug Carriers | 1 | 2017 | 81 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2017 | 303 | 0.140 |
Why?
|
| Insulin | 2 | 2010 | 1160 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1937 | 0.140 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 391 | 0.140 |
Why?
|
| Animals | 5 | 2017 | 26582 | 0.130 |
Why?
|
| Mice, Nude | 1 | 2017 | 790 | 0.130 |
Why?
|
| Cholesterol | 1 | 2017 | 356 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 363 | 0.130 |
Why?
|
| Middle Aged | 4 | 2022 | 25017 | 0.120 |
Why?
|
| Female | 7 | 2023 | 44509 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.110 |
Why?
|
| Learning Curve | 1 | 2021 | 18 | 0.100 |
Why?
|
| Male | 7 | 2023 | 40958 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2019 | 2261 | 0.090 |
Why?
|
| Adult | 5 | 2022 | 25640 | 0.090 |
Why?
|
| Preoperative Period | 1 | 2019 | 91 | 0.090 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 15 | 0.090 |
Why?
|
| Ileostomy | 1 | 2019 | 30 | 0.090 |
Why?
|
| Prognosis | 2 | 2016 | 3675 | 0.080 |
Why?
|
| Illinois | 1 | 2019 | 462 | 0.080 |
Why?
|
| Length of Stay | 1 | 2021 | 700 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2016 | 4212 | 0.080 |
Why?
|
| Biological Products | 1 | 2019 | 143 | 0.080 |
Why?
|
| cdc25 Phosphatases | 1 | 2016 | 18 | 0.070 |
Why?
|
| Reoperation | 1 | 2019 | 597 | 0.070 |
Why?
|
| Chemokines | 1 | 2016 | 73 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2016 | 252 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2021 | 751 | 0.060 |
Why?
|
| Patient Selection | 1 | 2019 | 685 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1804 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2016 | 679 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 269 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 250 | 0.060 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.060 |
Why?
|
| Contrast Media | 1 | 2019 | 1078 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2010 | 2378 | 0.060 |
Why?
|
| Mice | 1 | 2017 | 11352 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 797 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 559 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1685 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 1540 | 0.050 |
Why?
|
| United States | 2 | 2019 | 6665 | 0.050 |
Why?
|
| Prevalence | 1 | 2016 | 1239 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2023 | 184 | 0.050 |
Why?
|
| Chicago | 1 | 2016 | 1379 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2426 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1458 | 0.050 |
Why?
|
| KATP Channels | 1 | 2010 | 19 | 0.050 |
Why?
|
| Adolescent | 2 | 2016 | 8979 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 46 | 0.050 |
Why?
|
| Glucokinase | 1 | 2010 | 61 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2010 | 64 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 864 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3092 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 125 | 0.040 |
Why?
|
| Child | 2 | 2022 | 6926 | 0.040 |
Why?
|
| Aged | 2 | 2016 | 18402 | 0.040 |
Why?
|
| Syndrome | 1 | 2010 | 446 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3636 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 166 | 0.040 |
Why?
|
| Glyburide | 1 | 2008 | 32 | 0.040 |
Why?
|
| Sulfonylurea Receptors | 1 | 2008 | 50 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 195 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 378 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2008 | 207 | 0.040 |
Why?
|
| Pedigree | 1 | 2008 | 966 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2010 | 397 | 0.030 |
Why?
|
| Epilepsy | 1 | 2010 | 397 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2378 | 0.030 |
Why?
|
| Young Adult | 1 | 2016 | 5974 | 0.030 |
Why?
|
| Infant | 1 | 2008 | 3045 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2008 | 3611 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 3967 | 0.020 |
Why?
|